Navigation Links
Oramed Pharmaceuticals to Present at Rodman & Renshaw 13th Annual Global Investment Conference
Date:9/8/2011

JERUSALEM, September 8, 2011 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (OTC BB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, announced today that Roy Eldor, M.D., the Director of Medical Affairs at Oramed, is scheduled to present at the Rodman & Renshaw 13th Annual Global Investment Conference in the Israel track. The conference will be held at the Waldorf Astoria Hotel in New York City.

Dr Eldor is scheduled to speak on Tuesday September 13, 2011 at 1:35 p.m. ET in the Sutton Suite. He will discuss Oramed's strategic initiatives, updates and product pipeline.

For more information about the conference please visit http://www.rodm.com/2011conference

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research performed by top research scientists at Jerusalem's Hadassah Medical Center. Oramed's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com

Safe Harbor Statement

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the Company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the Company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the Company to differ materially from those expressed or implied in such forward looking statements. The Company undertakes no obligation to update or revise any forward-looking statements.


Company and Investor Relations Contacts:
Oramed Pharmaceuticals
Tara Horn
Office: +972-646-240-4193
Cell: +972-54-334-4318
Email: tara@oramed.com



'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule
2. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
3. Oramed Pharmaceuticals to Present at the 70th Scientific Sessions of the American Diabetes Association
4. Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd.
5. Oramed Pharmaceuticals Expands Scientific Advisory Board With the Appointment of John Amatruda, M.D.
6. Oramed Pharmaceuticals Announces Filing of Two Registration Statements
7. Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Societys Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)
8. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the 2009 British Pharmaceutical Conference in Manchester, England
9. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
10. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
11. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and ... 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will ... Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph ...
(Date:10/12/2017)... ... October 12, 2017 , ... In ... taxes a year. In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, ... overseas retirement havens have extremely low property-tax rates, which contributes to the relatively ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the University of California Berkeley, and other leading institutions in announcing the launch ... of institutions to change the way animals are raised for food. , Founding ...
(Date:10/12/2017)... ... October 12, 2017 , ... Nvision Biomedical ... staff with the addition of industry sales leader, Thomas (Tom) Slott, as Senior ... national distribution and sales network, direct the efforts of the surgical sales teams, ...
Breaking Medicine News(10 mins):